Cardiol Therapeutics (CRDL) Competitors C$1.40 -0.08 (-5.41%) As of 01:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock CRDL vs. DNA, VBV, CUS, AIM, ITH, FRX, IPA, APM, GXE, and GPHShould you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Dalradian Resources (DNA), VBI Vaccines (VBV), Chemtrade Electrochem Inc, (CUS), Aimia (AIM), International Tower Hill Mines (ITH), Fennec Pharmaceuticals (FRX), ImmunoPrecise Antibodies (IPA), Andean Precious Metals (APM), Gear Energy (GXE), and Graphite One (GPH). These companies are all part of the "pharmaceutical products" industry. Cardiol Therapeutics vs. Its Competitors Dalradian Resources VBI Vaccines Chemtrade Electrochem Inc, Aimia International Tower Hill Mines Fennec Pharmaceuticals ImmunoPrecise Antibodies Andean Precious Metals Gear Energy Graphite One Dalradian Resources (TSE:DNA) and Cardiol Therapeutics (TSE:CRDL) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership. Which has better earnings and valuation, DNA or CRDL? Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Dalradian Resources, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDalradian ResourcesN/AN/AN/A-C$0.03N/ACardiol TherapeuticsN/AN/A-C$42.93M-C$0.51-2.75 Do insiders and institutionals have more ownership in DNA or CRDL? 11.4% of Cardiol Therapeutics shares are held by institutional investors. 4.6% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is DNA or CRDL more profitable? Dalradian Resources' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dalradian ResourcesN/A N/A N/A Cardiol Therapeutics N/A -195.07%-54.15% Does the media prefer DNA or CRDL? In the previous week, Cardiol Therapeutics had 2 more articles in the media than Dalradian Resources. MarketBeat recorded 2 mentions for Cardiol Therapeutics and 0 mentions for Dalradian Resources. Cardiol Therapeutics' average media sentiment score of 0.37 beat Dalradian Resources' score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Dalradian Resources Neutral Cardiol Therapeutics Neutral SummaryCardiol Therapeutics beats Dalradian Resources on 5 of the 8 factors compared between the two stocks. Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDL vs. The Competition Export to ExcelMetricCardiol TherapeuticsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$116.17MC$2.15BC$5.46BC$6.36BDividend YieldN/A2.92%3.99%6.72%P/E Ratio-2.754.2729.9964.86Price / SalesN/A675.36375.551,651.63Price / Cash0.9810.3535.9483.29Price / Book9.3710.868.164.91Net Income-C$42.93MC$21.15BC$3.25BC$301.20M7 Day Performance-26.70%0.50%1.11%2.02%1 Month Performance-26.32%2.53%2.80%2.32%1 Year Performance-50.18%3.60%28.49%30.90% Cardiol Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDLCardiol TherapeuticsN/AC$1.40-5.4%N/A-43.5%C$116.17MN/A-2.7520News CoverageHigh Trading VolumeDNADalradian ResourcesN/AN/AN/AN/AC$519.02MN/A-56.15640VBVVBI VaccinesN/AN/AN/AN/AC$308.86MC$3.36M-4.9722CUSChemtrade Electrochem Inc,N/AN/AN/AN/AC$306.50MN/A0.0060AIMAimia2.4852 of 5 starsC$3.14-0.9%C$4.00+27.4%+15.6%C$302.00MC$464.71M-3.8620ITHInternational Tower Hill MinesN/AC$1.85+6.9%N/A+226.7%C$259.73MN/A-77.29220FRXFennec PharmaceuticalsN/AC$11.15+1.3%N/A+38.4%C$215.02MC$34.86M-188.8810Gap DownIPAImmunoPrecise AntibodiesN/AC$6.50+0.8%N/A+0.0%C$162.08MC$19.47M-7.3080Gap DownAPMAndean Precious Metals2.4141 of 5 starsC$1.29+7.5%C$2.00+55.0%+41.8%C$135.47MC$154.78M2.5530GXEGear EnergyN/AN/AN/AN/AC$126.52MC$134.93M10.391,310GPHGraphite OneN/AC$0.95-8.7%N/A+14.1%C$96.19MN/A-13.6620 Related Companies and Tools Related Companies Dalradian Resources Alternatives VBI Vaccines Alternatives Chemtrade Electrochem Inc, Alternatives Aimia Alternatives International Tower Hill Mines Alternatives Fennec Pharmaceuticals Alternatives ImmunoPrecise Antibodies Alternatives Andean Precious Metals Alternatives Gear Energy Alternatives Graphite One Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:CRDL) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredGold Hit $3,500. Here’s What’s Next…Gold just smashed through $3,500—and some experts believe that’s only the beginning. With big banks like Goldm...Reagan Gold Group | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
